Tumor cells with a cell cycle signature were prevalent in treatment-naive patients, whereas those with MYC/inflammatory signatures were dominant in progressive disease (PD) states after neoadjuvant chemotherapy or liver metastasis (Fig. 2G). The gene discussed is MYC; the disease is neoplasm.